Mirtazapine, Azamianserin, (RS)-2-Methyl-1,2,3,4,10,14b-hexahydropyranzino[2,1-a]pyrido[2,3-c]benzazepine, C17H19N3, M=265.36 g/mol
Trade Mark: Remeron®, Mepirepine®
Treatment of depressions.
Do not use with alcohol intoxication as well as heavy liver deseases. Do not use during pregnancy.
Combination with MAO inhibitors cause fever, cramps and unconsciousness.
The vegetative Adverse Effects are somewhat smaller than with the tricyclic antidepressants.
The blood level determination of Mirtazapine can take place after extraction by means of HPLC/DAD. Therapeutic blood levels: up to 0,3 µg/ml.